BNP Paribas Financial Markets lifted its holdings in uniQure (NASDAQ:QURE - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 468,357 shares of the biotechnology company's stock after buying an additional 41,166 shares during the period. BNP Paribas Financial Markets owned approximately 0.96% of uniQure worth $8,271,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Avoro Capital Advisors LLC purchased a new position in uniQure during the fourth quarter worth about $38,410,000. Franklin Resources Inc. purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $7,360,000. Boxer Capital Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth approximately $13,245,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of uniQure during the 4th quarter valued at approximately $9,473,000. Finally, Invesco Ltd. lifted its holdings in uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after acquiring an additional 502,684 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, CFO Christian Klemt sold 10,438 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the sale, the chief financial officer now directly owns 217,730 shares in the company, valued at approximately $2,240,441.70. This represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 6,717 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the completion of the sale, the chief executive officer now directly owns 580,795 shares in the company, valued at approximately $6,574,599.40. This trade represents a 1.14% decrease in their position. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock valued at $961,401 in the last three months. 4.74% of the stock is owned by corporate insiders.
uniQure Stock Up 4.7%
Shares of QURE stock traded up $0.60 during trading on Thursday, reaching $13.25. The company's stock had a trading volume of 1,149,238 shares, compared to its average volume of 1,866,682. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The stock's 50-day moving average price is $12.25 and its 200 day moving average price is $12.19. The company has a market capitalization of $725.78 million, a price-to-earnings ratio of -2.67 and a beta of 0.10. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.
uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.25. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, research analysts anticipate that uniQure will post -3.75 EPS for the current year.
Analyst Ratings Changes
QURE has been the subject of several recent analyst reports. StockNews.com raised uniQure to a "sell" rating in a research note on Tuesday, March 11th. Guggenheim reissued a "buy" rating and set a $28.00 price objective on shares of uniQure in a research report on Monday. Wells Fargo & Company reduced their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Chardan Capital reaffirmed a "buy" rating and set a $38.00 target price on shares of uniQure in a research note on Monday. Finally, HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of uniQure in a research report on Monday, April 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, uniQure currently has an average rating of "Moderate Buy" and a consensus price target of $37.82.
Get Our Latest Stock Report on QURE
About uniQure
(
Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Further Reading
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
